Zhen Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhen Zhou has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Joanne Ryan
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
18 shared publications - Rory Wolfe
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
15 shared publications - Robyn Lorraine Woods
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
13 shared publications - Mark Raymond Nelson
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
12 shared publications - John James McNeil
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
10 shared publications Mark R. Nelson
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
10 shared publications
Latest Publications
- 1 October 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (10) , 1375-1385
Longitudinal Changes in Heart Stress and the Risk for Cardiovascular Disease and Mortality in Older Adults
- 1 October 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (10) , 1375-1385
Longitudinal Changes in Heart Stress and the Risk for Cardiovascular Disease and Mortality in Older Adults
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (8) , e013687
Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE
BACKGROUND: Previous studies showed that the Pooled Cohort Equations substantially overestimate atherosclerotic cardiovascular disease (ASCVD) risk in older adults, and the recently published predicting risk of cardiovascular disease events (PREVENT) equation offers better performance. Identifying markers that can further refine risk estimates is essential for personalized prevention in this age group. This study evaluates the clinical utility of 6 markers for reclassifying intermediate-risk older adults (10-year PREVENT-estimated ASCVD risk, 7.5% to 20%), with a focus on de-escalation. METHODS: This post hoc analysis evaluated intermediate-risk older adults aged ≥70 years using data from ASPREE (Aspirin in Reducing Events in the Elderly; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583). ASPREE was a randomized trial of low-dose aspirin versus placebo in healthy older adults who were free of prior cardiovascular events at enrollment. Six markers were evaluated: the lowest quartile (Q1) of NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-TnI (high-sensitivity troponin I), and hs-CRP (high-sensitivity C-reactive protein), polygenic risk for lipoprotein(a) and polygenic risk for coronary artery disease, and absence of family history of ASCVD. Incident ASCVD events were adjudicated by expert panels. Statistical performance of each marker was assessed using diagnostic likelihood ratios, change in Harrell C statistic (ΔC), and net reclassification index relative to a baseline model incorporating variables included in the PREVENT equation. RESULTS: The study included 7764 participants (48% female; median age, 74 years [interquartile range, 72–77]), with a median follow-up of 10.3 years. During follow-up, 725 participants (9.3%) experienced ASCVD events. Q1 polygenic risk for coronary artery disease was the most powerful marker for down-grading risk, providing 37% risk reduction (diagnostic likelihood ratio: 0.627) and improving discrimination (ΔC: +1.44%; P =0.004) when compared with the baseline model, and correctly reclassifying 25.9% of nonevents downward (net reclassification index: 0.101). Q1 hs-TnI showed second-best performance (diagnostic likelihood ratio: 0.727; ΔC: +0.71%, net reclassification index: 0.075). CONCLUSIONS: Adding polygenic risk for coronary artery disease to the PREVENT equations may further personalize risk estimates and support clinical decision-making for older adults at intermediate risk for ASCVD events.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (8) , e013687
Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE
BACKGROUND: Previous studies showed that the Pooled Cohort Equations substantially overestimate atherosclerotic cardiovascular disease (ASCVD) risk in older adults, and the recently published predicting risk of cardiovascular disease events (PREVENT) equation offers better performance. Identifying markers that can further refine risk estimates is essential for personalized prevention in this age group. This study evaluates the clinical utility of 6 markers for reclassifying intermediate-risk older adults (10-year PREVENT-estimated ASCVD risk, 7.5% to 20%), with a focus on de-escalation. METHODS: This post hoc analysis evaluated intermediate-risk older adults aged ≥70 years using data from ASPREE (Aspirin in Reducing Events in the Elderly; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583). ASPREE was a randomized trial of low-dose aspirin versus placebo in healthy older adults who were free of prior cardiovascular events at enrollment. Six markers were evaluated: the lowest quartile (Q1) of NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-TnI (high-sensitivity troponin I), and hs-CRP (high-sensitivity C-reactive protein), polygenic risk for lipoprotein(a) and polygenic risk for coronary artery disease, and absence of family history of ASCVD. Incident ASCVD events were adjudicated by expert panels. Statistical performance of each marker was assessed using diagnostic likelihood ratios, change in Harrell C statistic (ΔC), and net reclassification index relative to a baseline model incorporating variables included in the PREVENT equation. RESULTS: The study included 7764 participants (48% female; median age, 74 years [interquartile range, 72–77]), with a median follow-up of 10.3 years. During follow-up, 725 participants (9.3%) experienced ASCVD events. Q1 polygenic risk for coronary artery disease was the most powerful marker for down-grading risk, providing 37% risk reduction (diagnostic likelihood ratio: 0.627) and improving discrimination (ΔC: +1.44%; P =0.004) when compared with the baseline model, and correctly reclassifying 25.9% of nonevents downward (net reclassification index: 0.101). Q1 hs-TnI showed second-best performance (diagnostic likelihood ratio: 0.727; ΔC: +0.71%, net reclassification index: 0.075). CONCLUSIONS: Adding polygenic risk for coronary artery disease to the PREVENT equations may further personalize risk estimates and support clinical decision-making for older adults at intermediate risk for ASCVD events.
- Top Cited Papers
- 1 July 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (8)
Global prevalence, trends, and dose-response associations of polypharmacy in older adults
Polypharmacy is common in older adults with comorbidities. This study aims to estimate its global prevalence, temporal trends, and dose-response associations with adverse health outcomes. PubMed, Embase, The Cochrane Library, Web of Science, and Scopus were searched from inception to June 30, 2025. Random-effects meta-analyses were used to pool prevalence estimates of polypharmacy based on mixed thresholds and relative risks. Study quality was assessed using Hoy’s method. Hazard ratios (HRs) from individual studies were synthesized using random-effects dose-response meta-analysis in studies that provided sufficient quantitative exposure information. A total of 545 studies, providing 565 prevalence estimates, were included, comprising 16 620 414 older adults from 56 countries worldwide. The pooled global prevalence of polypharmacy was 50.4% (95% confidence interval [CI]: 48.2%-52.7%; 95% prediction interval: 6.8%-93.5%). It demonstrated a significant increasing temporal trend in polypharmacy prevalence over calendar years. Compared with non-polypharmacy, polypharmacy was associated with a significantly higher risk of multiple adverse outcomes. Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95% CI: 1.03-1.06, p < .001), emergency (HR: 1.02, 95% CI: 1.02-1.03, p < .001), and hospital admission (HR: 1.04, 95% CI: 1.02-1.07, p < .001). Outcome-specific thresholds ranged from 4.55 to 5.46 medications. A pooled estimate of approximately five medications was obtained as a descriptive summary across outcomes. Polypharmacy affects approximately half of older adults worldwide and has increased steadily over time. It is associated with an increased risk of multiple adverse health outcomes, with risks increasing progressively as medication burden rises.
- 1 July 2026
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (8)
Top Cited PapersGlobal prevalence, trends, and dose-response associations of polypharmacy in older adults
Polypharmacy is common in older adults with comorbidities. This study aims to estimate its global prevalence, temporal trends, and dose-response associations with adverse health outcomes. PubMed, Embase, The Cochrane Library, Web of Science, and Scopus were searched from inception to June 30, 2025. Random-effects meta-analyses were used to pool prevalence estimates of polypharmacy based on mixed thresholds and relative risks. Study quality was assessed using Hoy’s method. Hazard ratios (HRs) from individual studies were synthesized using random-effects dose-response meta-analysis in studies that provided sufficient quantitative exposure information. A total of 545 studies, providing 565 prevalence estimates, were included, comprising 16 620 414 older adults from 56 countries worldwide. The pooled global prevalence of polypharmacy was 50.4% (95% confidence interval [CI]: 48.2%-52.7%; 95% prediction interval: 6.8%-93.5%). It demonstrated a significant increasing temporal trend in polypharmacy prevalence over calendar years. Compared with non-polypharmacy, polypharmacy was associated with a significantly higher risk of multiple adverse outcomes. Dose-response meta-analyses showed a monotonic increase in risk with each additional medication for mortality (HR: 1.05, 95% CI: 1.03-1.06, p < .001), emergency (HR: 1.02, 95% CI: 1.02-1.03, p < .001), and hospital admission (HR: 1.04, 95% CI: 1.02-1.07, p < .001). Outcome-specific thresholds ranged from 4.55 to 5.46 medications. A pooled estimate of approximately five medications was obtained as a descriptive summary across outcomes. Polypharmacy affects approximately half of older adults worldwide and has increased steadily over time. It is associated with an increased risk of multiple adverse health outcomes, with risks increasing progressively as medication burden rises.
- 28 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (8) , e214912
Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia
- 28 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (8) , e214912
Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia
- Open Access
- 21 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (3) , oeag036
Hospital-treated infectious diseases and polygenic susceptibility in relation to heart failure and cardiac remodelling: evidence from the UK Biobank and ARIC cohorts
Aims: Infectious diseases (IDs) are increasingly recognized as precipitants of heart failure (HF). However, the impact of diverse pathogens and genetic susceptibility on HF and cardiac remodelling remains unclear. Methods and results: We analysed 480 154 UK Biobank (UKB) participants and 9816 Atherosclerosis Risk in Communities (ARIC) participants free of HF at baseline. Hospital-treated IDs were ascertained with 931 ICD-10 codes and modelled as time-varying exposures. Incident HF and HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were identified through hospital records and adjudication. Polygenic risk scores (PRSs) for ID—overall and pathway-specific for TGF-β, acute inflammation, and myocardial fibrosis—were derived from genome-wide association study data. Multivariable Cox and Fine–Gray models estimated hazard ratios (HRs); cardiac structure and function were assessed by cardiac MRI in UKB and echocardiography in ARIC. Over median follow-up of 13.5 years (UKB) and 22.4 years (ARIC), any hospital-treated ID was associated with higher HF risk (UKB HR 1.54, 95% CI 1.46–1.63; ARIC HR 1.84, 1.68–2.00). Risks were similar for bacterial, viral, fungal, and parasitic infections, peaked within 180 days (HR 5.88), and persisted >1 year. Infectious diseases increased both HFpEF (sub-HR 1.81) and HFrEF (2.03). Imaging revealed higher left-ventricular mass, wall thickness, mass-to-volume ratio and filling pressures, and lower ejection fraction among infected individuals. In infection-free participants, higher overall ID-PRS predicted incident HF (per-SD HR 1.07 UKB; 1.11 ARIC) and adverse cardiac remodelling, with strongest effects for TGF-β and acute-inflammation pathways. Conclusion: Hospital-treated IDs and genetic predisposition to infection are independently associated with HF and adverse cardiac phenotypes. Integrating infection history and ID-PRS may enhance HF risk stratification and motivate trials targeting fibro-inflammatory pathways.
- 21 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (3) , oeag036
Open AccessHospital-treated infectious diseases and polygenic susceptibility in relation to heart failure and cardiac remodelling: evidence from the UK Biobank and ARIC cohorts
Aims: Infectious diseases (IDs) are increasingly recognized as precipitants of heart failure (HF). However, the impact of diverse pathogens and genetic susceptibility on HF and cardiac remodelling remains unclear. Methods and results: We analysed 480 154 UK Biobank (UKB) participants and 9816 Atherosclerosis Risk in Communities (ARIC) participants free of HF at baseline. Hospital-treated IDs were ascertained with 931 ICD-10 codes and modelled as time-varying exposures. Incident HF and HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were identified through hospital records and adjudication. Polygenic risk scores (PRSs) for ID—overall and pathway-specific for TGF-β, acute inflammation, and myocardial fibrosis—were derived from genome-wide association study data. Multivariable Cox and Fine–Gray models estimated hazard ratios (HRs); cardiac structure and function were assessed by cardiac MRI in UKB and echocardiography in ARIC. Over median follow-up of 13.5 years (UKB) and 22.4 years (ARIC), any hospital-treated ID was associated with higher HF risk (UKB HR 1.54, 95% CI 1.46–1.63; ARIC HR 1.84, 1.68–2.00). Risks were similar for bacterial, viral, fungal, and parasitic infections, peaked within 180 days (HR 5.88), and persisted >1 year. Infectious diseases increased both HFpEF (sub-HR 1.81) and HFrEF (2.03). Imaging revealed higher left-ventricular mass, wall thickness, mass-to-volume ratio and filling pressures, and lower ejection fraction among infected individuals. In infection-free participants, higher overall ID-PRS predicted incident HF (per-SD HR 1.07 UKB; 1.11 ARIC) and adverse cardiac remodelling, with strongest effects for TGF-β and acute-inflammation pathways. Conclusion: Hospital-treated IDs and genetic predisposition to infection are independently associated with HF and adverse cardiac phenotypes. Integrating infection history and ID-PRS may enhance HF risk stratification and motivate trials targeting fibro-inflammatory pathways.
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214572
Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia
Hearing loss is a risk factor of cognitive decline and dementia. We sought to investigate the effect of hearing aid (HA) use on cognition and dementia risk in older adults with hearing impairment. We emulated a target trial using data from Australian participants of the ASPirin in Reducing Events in the Elderly study. In the target trial, eligible participants were dementia-free, had moderate hearing impairment, and had no previous HA use. The treatment strategies were "use HAs" and "do not use HAs." Outcomes included overall cognition, dementia (DSM-IV criteria), and cognitive impairment (cognitive decline or dementia). The emulation used new HA prescription and frequency-of-use data measured by questionnaire, as well as cognition data from semiannual assessments over 7 years. Self-reported hearing problems were used as a proxy for moderate hearing impairment. Using the parametric g-formula, we estimated observational analogs of the intention-to-treat effect, using HA prescription to emulate allocation. Analyses for cognition outcomes were restricted to survivors. Multiple imputation was used for missing covariate and cognitive outcome data. We also emulated a second target trial with treatment strategies of (1) never, (2) rarely/sometimes, and (3) often/always use HAs. Across imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. The mean age was 75 years, and 48% were female. The estimated 7-year mean overall cognition scores among survivors were similar under HA prescription and no HA prescription (mean difference 0.03 SDs; 95% CI -0.14 to 0.21). The estimated 7-year risk of dementia was 5.0% under HA prescription and 7.5% under no HA prescription (risk ratio [RR] 0.67; 95% CI 0.37-0.97), and that of cognitive impairment was 36.1% under HA prescription and 42.4% under no HA prescription (RR 0.85; 95% CI 0.70-1.00). The risks of dementia and cognitive impairment were inversely associated with the frequency of HA use. We found that HA use in older people with hearing impairment may reduce dementia risk, although differences in age-related cognitive change were insubstantial. We cannot rule out residual confounding as an explanation for our findings. Long-term randomized trials of HAs for dementia risk are justified. This study provides Class III evidence that the use of hearing aids did not change overall cognitive scores in people 70 years and older with moderate hearing impairment as compared to those who used hearing aids.
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214572
Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia
Hearing loss is a risk factor of cognitive decline and dementia. We sought to investigate the effect of hearing aid (HA) use on cognition and dementia risk in older adults with hearing impairment. We emulated a target trial using data from Australian participants of the ASPirin in Reducing Events in the Elderly study. In the target trial, eligible participants were dementia-free, had moderate hearing impairment, and had no previous HA use. The treatment strategies were "use HAs" and "do not use HAs." Outcomes included overall cognition, dementia (DSM-IV criteria), and cognitive impairment (cognitive decline or dementia). The emulation used new HA prescription and frequency-of-use data measured by questionnaire, as well as cognition data from semiannual assessments over 7 years. Self-reported hearing problems were used as a proxy for moderate hearing impairment. Using the parametric g-formula, we estimated observational analogs of the intention-to-treat effect, using HA prescription to emulate allocation. Analyses for cognition outcomes were restricted to survivors. Multiple imputation was used for missing covariate and cognitive outcome data. We also emulated a second target trial with treatment strategies of (1) never, (2) rarely/sometimes, and (3) often/always use HAs. Across imputed data sets, a median of 2,777 eligible individuals were included, with a median of 664 receiving a new HA prescription. The mean age was 75 years, and 48% were female. The estimated 7-year mean overall cognition scores among survivors were similar under HA prescription and no HA prescription (mean difference 0.03 SDs; 95% CI -0.14 to 0.21). The estimated 7-year risk of dementia was 5.0% under HA prescription and 7.5% under no HA prescription (risk ratio [RR] 0.67; 95% CI 0.37-0.97), and that of cognitive impairment was 36.1% under HA prescription and 42.4% under no HA prescription (RR 0.85; 95% CI 0.70-1.00). The risks of dementia and cognitive impairment were inversely associated with the frequency of HA use. We found that HA use in older people with hearing impairment may reduce dementia risk, although differences in age-related cognitive change were insubstantial. We cannot rule out residual confounding as an explanation for our findings. Long-term randomized trials of HAs for dementia risk are justified. This study provides Class III evidence that the use of hearing aids did not change overall cognitive scores in people 70 years and older with moderate hearing impairment as compared to those who used hearing aids.
- Top Cited Papers
- 12 January 2026
- Published by Springer Nature in GeroScience
- Vol. 48 (6) , 1-16
Association between cardiovascular-kidney-metabolic syndrome and risks of 14 age-related health outcomes in primary prevention older population
Background The American Heart Association (AHA) recently introduced a new clinical entity; the cardiovascular-kidney-metabolic syndrome (CKMS), to promote a multi-disciplinary approach for chronic disease management. This study aims to investigate the relationship between CKMS and major adverse outcomes in older populations in primary care. Methods This study utilized data from 18,367 community-dwelling individuals aged ≥ 65, free from prior cardiovascular disease (CVD). Participants were classified into four CKMS stages (stage 0-no CKMS risk factor to stage 3-high CKMS risk) at baseline based on the AHA definition. The association with 14 health outcomes was analysed using multivariable cause-specific hazard models. Additional stratifications were performed by social disadvantage, inflammation levels, and number of CKMS components within each stage to refine risk staging. Results Over a median follow-up of 8.6 years, the prevalence of CKMS stages 0 to 3 was 2.8%, 8.2%, 52.6%, and 36.0%, respectively. Compared to stage 0, stage 3 associated with all-cause mortality (HR 1.31, 95%CI 1.01–1.69), CVD mortality (3.11, 1.46–6.60), incident total CVD events (2.78, 1.86–4.15), myocardial infarction (2.37, 1.21–4.62), stroke (2.75, 1.50–5.04), heart failure hospitalization (4.56, 1.45–14.37), atrial fibrillation (2.63, 1.61–4.29), cancer (1.31, 1.04–1.64), depression (1.20, 1.04–1.39), and physical disability (1.92, 1.20–3.08). Social disadvantage, high inflammation, and CKMS component count further amplified these associations. No linear trend was observed for cognitive outcomes and non-CVD cause-specific mortality. Conclusion This study is the first to establish relationships between CKMS and multiple age-related outcomes in older adults, providing critical insights for developing holistic approaches to primary care in the aged. Graphical Abstract
- 12 January 2026
- Published by Springer Nature in GeroScience
- Vol. 48 (6) , 1-16
Top Cited PapersAssociation between cardiovascular-kidney-metabolic syndrome and risks of 14 age-related health outcomes in primary prevention older population
Background The American Heart Association (AHA) recently introduced a new clinical entity; the cardiovascular-kidney-metabolic syndrome (CKMS), to promote a multi-disciplinary approach for chronic disease management. This study aims to investigate the relationship between CKMS and major adverse outcomes in older populations in primary care. Methods This study utilized data from 18,367 community-dwelling individuals aged ≥ 65, free from prior cardiovascular disease (CVD). Participants were classified into four CKMS stages (stage 0-no CKMS risk factor to stage 3-high CKMS risk) at baseline based on the AHA definition. The association with 14 health outcomes was analysed using multivariable cause-specific hazard models. Additional stratifications were performed by social disadvantage, inflammation levels, and number of CKMS components within each stage to refine risk staging. Results Over a median follow-up of 8.6 years, the prevalence of CKMS stages 0 to 3 was 2.8%, 8.2%, 52.6%, and 36.0%, respectively. Compared to stage 0, stage 3 associated with all-cause mortality (HR 1.31, 95%CI 1.01–1.69), CVD mortality (3.11, 1.46–6.60), incident total CVD events (2.78, 1.86–4.15), myocardial infarction (2.37, 1.21–4.62), stroke (2.75, 1.50–5.04), heart failure hospitalization (4.56, 1.45–14.37), atrial fibrillation (2.63, 1.61–4.29), cancer (1.31, 1.04–1.64), depression (1.20, 1.04–1.39), and physical disability (1.92, 1.20–3.08). Social disadvantage, high inflammation, and CKMS component count further amplified these associations. No linear trend was observed for cognitive outcomes and non-CVD cause-specific mortality. Conclusion This study is the first to establish relationships between CKMS and multiple age-related outcomes in older adults, providing critical insights for developing holistic approaches to primary care in the aged. Graphical Abstract
- Open Access
- 30 December 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (3)
Serum uric acid levels and longitudinal change in cognitive function in older adults: a sex-stratified population-based study
Background: Serum uric acid (SUA) has been linked to cognitive function, but sex-specific associations remain unclear. Biological differences in SUA levels between sexes, driven by hormonal and renal factors, highlight the importance of sex-stratified analysis. This study examined the association between SUA levels and changes in cognitive function in older adults. Methods: A total of 11 411 community-dwelling ASPirin in Reducing Events in the Elderly participants, free from dementia at baseline and with valid SUA measurements, were included. The Modified Mini-Mental State Examination (3MS), Hopkins Verbal Learning Test–Revised (HVLT-R), Symbol Digit Modalities Test, and Controlled Oral Word Association Test were used to assess cognition at baseline and over a median follow-up of 9 years. Separate linear mixed-effects regression models in males and females were fitted to assess the associations between SUA levels and change in cognitive function over time. Results: Females in the lowest SUA quintile (Q1) had significant declines in the measure of global cognition (3MS: β ±SE= −0.07 ± 0.03, p = .02) and episodic memory (HVLT-R; delayed recall: β±SE= -0.03 ± 0.01, p = .02) compared to the middle quintiles (Q2-Q4), but the highest SUA quintile (Q5) was not associated with decline. No associations were observed for executive function, verbal fluency, or psychomotor speed. In males, no significant associations between SUA levels and change in cognitive function were observed. Conclusion: Low SUA levels were linked to decline in the measure of global cognition and episodic memory among females but not males. High SUA levels were not associated with cognitive decline. Managing SUA levels within the physiological range may support cognitive health, particularly in older females.
- 30 December 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 81 (3)
Open AccessSerum uric acid levels and longitudinal change in cognitive function in older adults: a sex-stratified population-based study
Background: Serum uric acid (SUA) has been linked to cognitive function, but sex-specific associations remain unclear. Biological differences in SUA levels between sexes, driven by hormonal and renal factors, highlight the importance of sex-stratified analysis. This study examined the association between SUA levels and changes in cognitive function in older adults. Methods: A total of 11 411 community-dwelling ASPirin in Reducing Events in the Elderly participants, free from dementia at baseline and with valid SUA measurements, were included. The Modified Mini-Mental State Examination (3MS), Hopkins Verbal Learning Test–Revised (HVLT-R), Symbol Digit Modalities Test, and Controlled Oral Word Association Test were used to assess cognition at baseline and over a median follow-up of 9 years. Separate linear mixed-effects regression models in males and females were fitted to assess the associations between SUA levels and change in cognitive function over time. Results: Females in the lowest SUA quintile (Q1) had significant declines in the measure of global cognition (3MS: β ±SE= −0.07 ± 0.03, p = .02) and episodic memory (HVLT-R; delayed recall: β±SE= -0.03 ± 0.01, p = .02) compared to the middle quintiles (Q2-Q4), but the highest SUA quintile (Q5) was not associated with decline. No associations were observed for executive function, verbal fluency, or psychomotor speed. In males, no significant associations between SUA levels and change in cognitive function were observed. Conclusion: Low SUA levels were linked to decline in the measure of global cognition and episodic memory among females but not males. High SUA levels were not associated with cognitive decline. Managing SUA levels within the physiological range may support cognitive health, particularly in older females.